TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals at least 18 years of age with a diagnosis of PNH \& vaccination against meningococcus.~Exclusion Criteria:~* Abnormal renal or liver function~* History of meningococcal disease~* History of Guillain-Barre syndrome~* Known infection with HIV or Hepatitis B or C~* History of thrombotic events

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TT30 (ALXN1102 Formulation) (Type: EXPERIMENTAL): IV: 0.1, 0.3, and 1.0 mg/kg
- TT30 (ALXN1103 Formulation) (Type: EXPERIMENTAL): IV: 3.0, 6.0, and 10.0 mg/kg~SC: 1.0 and 3.0 mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Acetaminophen vs Placebo in the Pre-operative Setting and Outcomes on Post-operative Pain, Nausea and Vomiting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Each of the following must be met:~* Greater than or equal to 18 years of age.~* Female~* Undergoing outpatient breast surgery (unilateral or bilateral surgery)~Exclusion Criteria:~If ANY of the following apply:~* History of an allergy or hypersensitivity to acetaminophen (oral, rectal, or IV)~* Chronic alcoholism~* Severe deficiency of liver and/or kidney~* Any patient unable to sign informed consent~* Pregnancy~* Any patient currently enrolled in another experimental protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV acetaminophen (Type: ACTIVE_COMPARATOR): Patients in the IV acetaminophen arm will receive a one gram dose of IV acetaminophen in the pre-operative area prior to their surgery.
- Placebo (Type: PLACEBO_COMPARATOR): Patients in the placebo arm will receive normal saline in the pre-operative area.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Anterior Cruciate Ligament Reconstruction: Residual Rotational Laxity for Single Versus Double Bundle Techniques

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient must have given his/her informed and signed consent~* The patient must be insured or beneficiary of a health insurance plan~* The patient is available for 24 months of follow-up~* The patient requires reconstruction of the anterior cruciate ligament due to rupture confirmed by MRI~Exclusion Criteria:~* The patient is in an exclusion period determined by a previous study~* The patient is under judicial protection, under tutorship or curatorship~* The patient refuses to sign the consent~* It is impossible to correctly inform the patient~* The patient is pregnant~* The patient is breastfeeding~* The patient require a single bundle, KJ-type surgical technique~* Contra-indication for MRI scans

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Bundle (Type: ACTIVE_COMPARATOR): These patients are operated using a single bundle technique.
- Double bundle (Type: EXPERIMENTAL): These patients are operated using a double bundle technique.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Riluzole and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed solid tumor~* Has ≥ 2 brain metastases as demonstrated by baseline MRI~  * Patients with only 1 metastasis are eligible provided the metastasis is too large for radiosurgery and not amenable to surgical resection~* Not being considered for surgical resection~* Eligible to undergo whole-brain radiotherapy (WBRT)~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* ANC ≥ 1,000/μL~* Platelet count ≥ 50,000/μL~* Total bilirubin ≤ 1.5 times upper limit of normal (ULN)~* AST/ALT ≤ 1.5 times ULN~* INR ≤ 1.5 times ULN~* Sodium normal~* Thyroid-stimulating hormone normal~* Negative pregnancy test~* Fertile patients must use effective contraception before, during, and for ≥ 6 months after completion of study treatment~* No headaches, disequilibrium, vertigo, or dizziness~* No known history of hepatitis B or C~* No concurrent serious systemic disorder (including active infection) that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator~* No history of allergic reactions attributed to riluzole~PRIOR CONCURRENT THERAPY:~* No prior WBRT~* At least 2 weeks since prior systemic chemotherapy~* No systemic chemotherapy during and for ≥ 3 weeks after completion of WBRT~* Radiosurgical boosts to ≤ 3 metastases allowed, based on the discretion of the treating radiation oncologist

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Riluzole; Radiation Therapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: REFRESH: Receptivity Enhancement by Follicular-phase Renewal After Endometrial ScratcHing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fresh IVF/ICSI cycle~* Antagonist down-regulation~* Signed informed consent~Exclusion Criteria:~* Other known reasons for impaired implantation (i.e. hydrosalpinx, fibroid distorting the endometrial cavity, Asherman's syndrome, thrombophilia or endometrial tuberculosis)~* Oocyte donation acceptors~* Frozen egg transfers~* Embryos planned to undergo preimplantation genetic diagnosis (PGD)~* BMI \>35 or \<18~* Women already recruited for another trial on medically assisted procreation during the same cycle~* Women who have previously enrolled in the trial~* Those unable to comprehend the investigational nature of the proposed study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Control arm (Type: NO_INTERVENTION): Women undergoing exogenous gonadotropin ovarian stimulation for ART in an antagonist downregulated cycle.
- Induced endometrial injury arm (Type: EXPERIMENTAL): Women undergoing exogenous gonadotropin ovarian stimulation for ART in an antagonist downregulated cycle. Additionally, they will undergo an endometrial biopsy on the 6th day of ovarian stimulation using a Pipelle de Cornier® (CCD International, Paris, France).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and females~* 18 and 50 years of age~* Diagnosis of schizophrenia~* Chronic cannabis users who have used for at least 1 year~* Using cannabis at least once weekly~* Currently being treated with antipsychotic medication~* Must be on a the same dose of antipsychotic medication for at least 3 months.~* Females of childbearing potential must use an adequate form of birth control while participating.~* Participants will be required to have blood pressures greater than 90/60 and less than 140/90.~Exclusion Criteria:~* Use of illicit drugs other than cannabis~* Any psychiatric hospitalizations within 3 months~* pregnancy in females~* taking clozapine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- dronabinol (Type: ACTIVE_COMPARATOR): dronabinol 10 mg one capsule by mouth at 8:00 a.m.
- sugar pill (Type: PLACEBO_COMPARATOR): one capsule given by mouth at 8:00 a.m.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female participants \> 18 years of age, with chronic kidney disease (CKD) stage V;~* Participants with diagnosis of calcitriol resistance defined as: Episodes of hypercalcemia and/or hyperphosphatemia (defined as an episode of calcium or phosphorus above Upper Limit of Normal or documented by medical history stating that the treatment with calcitriol was discontinued due to hypercalcemia and/or hyperphosphatemia) that precludes treatment continuation and/or persistent PTH above 600pg/mL during the calcitriol therapy;~* PTH value at screening visit between 600 pg/mL and 2,000 pg/mL;~* Stable clinical conditions;~* Participant has voluntarily consented to participate in the study, by signing and dating an informed consent form, approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), after the nature of the study has been explained and all his questions about the study have been elucidated. The informed consent must be signed before any study-specific procedures are performed.~Exclusion Criteria:~* Previous parathyroidectomy;~* Presence of hypercalcemia (corrected Ca \> 10.5 mg/dL) and/or hyperphosphatemia (P \> 6.0 mg/dL) and/or Ca x P product \> 60, at screening visit (corrected Ca calculated by: \[4 - participant's serum albumin (g/dL)\] x 0.8 + participant's serum Ca value);~* Severe and/or unstable clinical conditions, e.g., congestive heart failure, advanced cancer, advanced HIV disease, severe endocrinopathies, uncompensated diabetes mellitus, life-threatening cardiac arrhythmias, etc;~* Abnormal liver tests (\> 1.5 times above upper limit of normal);~* Pregnant or breast-feeding women;~* Evidence of vitamin D toxicity;~* Known hypersensitivity to any study drug components.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Calcitriol challenge followed by paricalcitol (Type: OTHER): Participants began a controlled calcitriol therapy period (calcitriol challenge) to confirm calcitriol resistance. After this period, those who failed to reduce PTH (according to parameters in protocol) initiated paricalcitol therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intraoperative Imaging of Pituitary Adenomas by OTL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients over 18 years of age~2. Patients presenting with a pituitary nodule presumed to be resectable on pre-operative assessment~3. Good operative candidate~4. Subject capable of giving informed consent and participating in the process of consent.~Exclusion Criteria:~1. Pregnant women as determined by urinary or serum beta human chorionic gonadotropin (hCG) within 72 hours of surgery~2. Patients with a history of anaphylactic reactions to OTL38~3. Patients with a known allergy to Benadryl~4. Previous exposure to OTL38

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OTL38 (Type: EXPERIMENTAL): Dosage calculated by weight of individual

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Use of a Silastic Spring-Loaded Silo for Infants With Gastroschisis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Gastroschisis~* Birth Weight ≥ 1500 grams~* Gestational Age ≥ 34 weeks~Exclusion Criteria:~* Birth Weight \< 1500 grams~* Gestational Age \< 34 weeks~* Presence of Bowel Ischemia or Necrosis~* Abdominal wall defect too small~* Major associated anomalies or medical condition~* Presence of Intracranial Hemorrhage (grade IV)~* Parent Refusal for Randomization

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 30 Days
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Silastic Spring-Loaded Silo
- 2 (Type: ACTIVE_COMPARATOR): Primary Closure of Abdomen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cost-utility Analysis of the Use of the Paro Robotic Seal by Elderly Patients With Moderate or Severe Cognitive Disorders in Institutions: a Randomised Study.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over 70 years of age~* With moderate or severe neurocognitive disorders of any etiology (Mini Mental State Examination (MMSE) less than or equal to 20, or not feasible)~* Resident in EHPAD (establishment for dependent elderly people) or USLD (long-term care unit ) in permanent accommodation for more than 1 month at inclusion~Exclusion Criteria:~* Patient with presumed life expectancy of less than 3 months~* Mini Mental State Examination (MMSE) not feasible for any reason other than cognitive impairment (e.g. stroke aphasia), without dementia~* Known carrier of multi-drug resistant bacteria~* Carrier of Pace-maker (precautionary advice from manufacturer)~* Refusal to participate to the study (trusted person, guardian or curator or patient depending on the patient's mental state)~* Patient under court protection~* Prior inclusion in an interventional study that may alter the interpretation of the results of the analysis~* Patient not affiliated to a social security system or beneficiary of such a system

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- With robotic seal PARO (Type: EXPERIMENTAL): The robot will be made available to the patient by the caregiver in charge of the patient for 5 minutes before a toilet and for the duration of the treatment (about 10 minutes), twice a week for 16 weeks.
- Without robotic seal PARO (Type: NO_INTERVENTION): The care of the patient during the toilet will be carried out according to the modalities currently in use in the facility.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Colorectal Screening Strategies in Underserved Populations

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Any Gender~* 45-64 years of age~* Able to sign the informed consent form~* Meets eligibility criteria to participate in New Jersey Cancer Education Early Detection Community Outreach Program~  * Uninsured/underinsured~ * Household income \<250% Federal Poverty Level~ * Must be New Jersy resident~* Must have Smart phone~* Must speak English or Spanish~Exclusion Criteria:~* History of colon cancer, colon/rectal polyps and rectal bleeding~* Individuals with Dementia~* ECOG Performance Status 3-4~* Prior Colonoscopy within past 10 years

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 64 Years
- Healthy Volunteers: None

Study Arms:
- Telephone Prompt (Type: None): Following consent, the Research Team will call participants three times in the first month (within the first week of signing consent at week 2 and repeated at week 3) and then one time per month for the following two months with scripted messaging reminding the participant to complete the screening activity (colonoscopy or fecal test). Interpreter services via phone will be utilized for non-English speaking participants.
- Digital Prompt (Type: None): Following consent, scripted messaging will be sent three times in the first month (within the first week of signing consent at week 2 and repeated at week 3) and then once time per month for the following two months with scripted messaging reminding the participant to complete the screening activity (colonoscopy or fecal test). Digital prompts will be available in Spanish and English.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Ventilator Associated Pneumonia and Late Complications of Percutaneous Tracheostomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* all patients on the intensive care unit who receive a tracheostomy.~Exclusion Criteria:~* HIV/AIDS~* use of immunosuppressive~* with regard to the MRI-scan patients who have a pacemaker and/or who are claustrophobic

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- subglottic drainage (Type: ACTIVE_COMPARATOR): suctioning of subglottis with cannula

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Calcitriol in Preventing Prostate Cancer in Patients With Prostatic Intraepithelial Neoplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed high-grade prostatic intraepithelial neoplasia~  * Diagnosed within the past 6 months~* No evidence of prostate cancer within the past 6 months~* No evidence of palpable nodules on digital rectal exam~* Prostate specific antigen ≤ 10 ng/mL within the past 3 months~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-1~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic~* SGOT and SGPT ≤ 1.5 times upper limit of normal~Renal~* No uncontrolled renal failure~* No cancer-related hypercalcemia or kidney stones within the past 5 years~Cardiovascular~* No uncontrolled coronary artery disease~* No uncontrolled congestive heart failure~Other~* Prior malignancy allowed provided patient was curatively treated and has been disease-free for an appropriate time period for the specific cancer~* No known HIV positivity~* No active infection~* No major depression or suicidal ideation~* No other condition that would preclude study compliance~* No other uncontrolled medical condition~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior chemotherapy for any malignancy~Endocrine therapy~* At least 2 weeks since prior and no concurrent finasteride (Prosear® or Propecia®) or other androgen suppressor~* No concurrent corticosteroids~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* At least 2 weeks since prior phenytoin or phenobarbital~* At least 2 weeks since prior ketoconazole~* No concurrent administration of any of the following:~  * Magnesium-containing antacids~ * Thiazide diuretics~ * Calcium supplements~ * Digoxin~ * Herbal supplements~ * Pharmacological doses of cholecalciferol (vitamin D) or its derivatives

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive oral calcitriol once daily for 8 weeks. Treatment repeats every 8 weeks for 2 courses. After completion of course 2 (week 16), patients undergo biopsy. Patients continue to receive calcitriol for up to 3 additional weeks while the biopsy is being evaluated. Patients with persistent high-grade prostatic intraepithelial neoplasia (HGPIN) by biopsy receive 2 additional courses of calcitriol.
- Arm II (Type: OTHER): Patients undergo observation for 16 weeks. At week 16, patients undergo biopsy. Patients with persistent HGPIN by biopsy receive 2 courses of calcitriol as in arm I.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues